Country Trust Bank Buys 1,300 Shares of Danaher Co. (NYSE:DHR)

Country Trust Bank grew its stake in Danaher Co. (NYSE:DHR) by 726.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,479 shares of the conglomerate’s stock after acquiring an additional 1,300 shares during the period. Country Trust Bank’s holdings in Danaher were worth $411,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Tsfg LLC raised its stake in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth about $25,000. nVerses Capital LLC bought a new position in shares of Danaher in the second quarter worth about $25,000. Redmont Wealth Advisors LLC bought a new stake in shares of Danaher during the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. bought a new stake in shares of Danaher during the fourth quarter worth approximately $42,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 0.0 %

Danaher stock opened at $268.81 on Wednesday. The stock has a market capitalization of $199.10 billion, a PE ratio of 45.56, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a 50 day moving average of $271.01 and a 200-day moving average of $258.75.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.05 earnings per share. On average, equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Barclays boosted their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Finally, Stifel Nicolaus boosted their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.